A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects who Completed Preceding Study M13-390 with Adalimumab

The study objective is to assess the long-term safety, tolerability, efficacy, and the immunogenicity of the 100 mg/mL adalimumab formulation.